Grantham Mayo Van Otterloo & Co. LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Grantham Mayo Van Otterloo & Co. LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,979 shares of the biopharmaceutical company’s stock after buying an additional 10,982 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Regeneron Pharmaceuticals were worth $44,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of REGN. Quantbot Technologies LP bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $151,000. Integrated Wealth Concepts LLC lifted its stake in shares of Regeneron Pharmaceuticals by 40.1% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 748 shares of the biopharmaceutical company’s stock valued at $786,000 after acquiring an additional 214 shares during the last quarter. IHT Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 17.2% in the 3rd quarter. IHT Wealth Management LLC now owns 701 shares of the biopharmaceutical company’s stock valued at $736,000 after acquiring an additional 103 shares during the last quarter. Royal London Asset Management Ltd. grew its position in Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Royal London Asset Management Ltd. now owns 43,675 shares of the biopharmaceutical company’s stock worth $45,913,000 after acquiring an additional 1,152 shares during the last quarter. Finally, Quantinno Capital Management LP increased its stake in Regeneron Pharmaceuticals by 59.9% in the 3rd quarter. Quantinno Capital Management LP now owns 7,473 shares of the biopharmaceutical company’s stock worth $7,856,000 after purchasing an additional 2,798 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent analyst reports. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. TD Cowen cut their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Bernstein Bank dropped their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Citigroup reduced their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Stock Down 6.1 %

REGN stock opened at $573.45 on Friday. The business has a 50 day moving average of $676.70 and a 200 day moving average of $781.68. The firm has a market cap of $62.69 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a twelve month low of $572.00 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $11.86 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.